Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank.

Andrew R English Bodhayan PrasadDeclan H McGuiganGeraldine HoriganMaurice O'KaneAnthony J BjoursonPriyank ShuklaCatriona KellyPaula L McClean

Published in: Endocrinology, diabetes & metabolism (2022)

Simvastatin is associated with superior lipid and glycaemic control to atorvastatin in those with and without T2DM, and with fewer incident T2DM cases. Given the importance of lipid and glycaemic control in preventing secondary complications of T2DM, these findings may help inform prescribing practices.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
primary care
fatty acid
healthcare
insulin resistance
risk factors
metabolic syndrome
adverse drug